Risk factors for breast cancer according to estrogen and progesterone receptor status
- PMID: 14759989
- DOI: 10.1093/jnci/djh025
Risk factors for breast cancer according to estrogen and progesterone receptor status
Abstract
Background: Evaluations of epidemiologic risk factors in relation to breast cancer classified jointly by estrogen receptor (ER) and progesterone receptor (PR) status have been inconsistent. To address this issue, we conducted a prospective evaluation of risk factors for breast cancer classified according to receptor status.
Methods: During 1 029 414 person-years of follow-up of 66 145 women participating in the Nurses' Health Study from 1980 through 2000, we identified 2096 incident cases of breast cancer for which information on ER/PR status was available: 1281 were ER+/PR+, 318 were ER+/PR-, 80 were ER-/PR+, and 417 were ER-/PR-. We fit a log-incidence model of breast cancer and used polychotomous logistic regression to compare coefficients for breast cancer risk factors in patients with different ER/PR status. To test for differences in risk factor odds ratios based on marginal ER/PR categories, we evaluated ER status controlling for PR status and vice versa. The predictive ability of our log-incidence model to discriminate between women who would develop ER+/PR+ breast cancer and those who would not (and similarly for ER-/PR- breast cancer) was evaluated by using receiver operator characteristic curve analysis. All statistical tests were two-sided.
Results: We observed statistically significant heterogeneity among the four ER/PR categories for some risk factors (age, menopausal status, body mass index [BMI] after menopause, the one-time adverse effect of first pregnancy, and past use of postmenopausal hormones) but not for others (benign breast disease, family history of breast cancer, alcohol use, and height). The one-time adverse association of first pregnancy with incidence was present for PR- but not for PR+ tumors after controlling for ER status (P =.007). However, the association of BMI after menopause with incidence was present for PR+ but not PR- tumors (P =.005). Statistically significant differences in the incidence of ER+ and ER- tumors were seen with age, both before and after menopause (P =.003), and with past use of postmenopausal hormones (P =.01). Area under the receiver operator characteristic curve, adjusted for age, was 0.64 (95% confidence interval [CI] = 0.63 to 0.66) for ER+/PR+ tumors and 0.61 (95% CI = 0.58 to 0.64) for ER-/PR- tumors.
Conclusions: Incidence rates and risk factors for breast cancer differ according to ER and PR status. Thus, to accurately estimate breast cancer risk, breast cancer cases should be divided according to the ER and PR status of the tumor.
Similar articles
-
Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.J Natl Cancer Inst. 2005 Nov 2;97(21):1601-8. doi: 10.1093/jnci/dji341. J Natl Cancer Inst. 2005. PMID: 16264180
-
Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status.Genet Epidemiol. 1996;13(2):207-21. doi: 10.1002/(SICI)1098-2272(1996)13:2<207::AID-GEPI6>3.0.CO;2-4. Genet Epidemiol. 1996. PMID: 8722747 Clinical Trial.
-
Predicting risk of breast cancer in postmenopausal women by hormone receptor status.J Natl Cancer Inst. 2007 Nov 21;99(22):1695-705. doi: 10.1093/jnci/djm224. Epub 2007 Nov 13. J Natl Cancer Inst. 2007. PMID: 18000216
-
Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.Breast Cancer Res Treat. 2010 Oct;123(3):641-9. doi: 10.1007/s10549-010-1116-4. Epub 2010 Aug 15. Breast Cancer Res Treat. 2010. PMID: 20711809 Review.
-
Etiology of hormone receptor-defined breast cancer: a systematic review of the literature.Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15466970 Review.
Cited by
-
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women.Oncologist. 2015 Jul;20(7):713-8. doi: 10.1634/theoncologist.2014-0412. Epub 2015 May 29. Oncologist. 2015. PMID: 26025931 Free PMC article.
-
Application of the Key Characteristics Framework to Identify Potential Breast Carcinogens Using Publicly Available in Vivo, in Vitro, and in Silico Data.Environ Health Perspect. 2024 Jan;132(1):17002. doi: 10.1289/EHP13233. Epub 2024 Jan 10. Environ Health Perspect. 2024. PMID: 38197648 Free PMC article.
-
A simplified risk scoring system for predicting high-risk groups in gene expression tests for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and node-positive breast cancer.Ann Surg Treat Res. 2023 Dec;105(6):360-368. doi: 10.4174/astr.2023.105.6.360. Epub 2023 Nov 29. Ann Surg Treat Res. 2023. PMID: 38076600 Free PMC article.
-
Early Life Residence, Fish Consumption, and Risk of Breast Cancer.Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):346-354. doi: 10.1158/1055-9965.EPI-16-0473-T. Epub 2016 Oct 10. Cancer Epidemiol Biomarkers Prev. 2017. PMID: 27765796 Free PMC article.
-
The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer.BJS Open. 2021 May 7;5(3):zrab040. doi: 10.1093/bjsopen/zrab040. BJS Open. 2021. PMID: 34013318 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous